Cargando…

β-Thalassemia and ocular implications: a systematic review

BACKGROUND: Beta-thalassemia is a severe genetic blood disorder caused by a mutation in the gene encoding for the beta chains of hemoglobin. Individuals with beta-thalassemia major require regular lifelong Red Blood Cell transfusions to survive. Ocular involvement is quite common and may have seriou...

Descripción completa

Detalles Bibliográficos
Autores principales: Liaska, Aliki, Petrou, Petros, Georgakopoulos, Constantinos D., Diamanti, Ramza, Papaconstantinou, Dimitris, Kanakis, Menelaos G., Georgalas, Ilias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938965/
https://www.ncbi.nlm.nih.gov/pubmed/27390837
http://dx.doi.org/10.1186/s12886-016-0285-2
_version_ 1782441934973829120
author Liaska, Aliki
Petrou, Petros
Georgakopoulos, Constantinos D.
Diamanti, Ramza
Papaconstantinou, Dimitris
Kanakis, Menelaos G.
Georgalas, Ilias
author_facet Liaska, Aliki
Petrou, Petros
Georgakopoulos, Constantinos D.
Diamanti, Ramza
Papaconstantinou, Dimitris
Kanakis, Menelaos G.
Georgalas, Ilias
author_sort Liaska, Aliki
collection PubMed
description BACKGROUND: Beta-thalassemia is a severe genetic blood disorder caused by a mutation in the gene encoding for the beta chains of hemoglobin. Individuals with beta-thalassemia major require regular lifelong Red Blood Cell transfusions to survive. Ocular involvement is quite common and may have serious implications. METHODS: Extensive review of observational studies on beta-thalassemia, to determine the prevalence and spectrum of ocular abnormalities, by clinical examination and multimodal imaging, and to investigate risk factors for their development. RESULTS: Frequency of ocular involvement differs among various studies (41.3–85 %, three studies). Ocular findings in beta-thalassemia may correlate to the disease itself, iron overload or the chelating agents used. Beta-thalassemia ocular manifestations include ocular surface disease, as demonstrated by tear function parameters (two studies). Lens opacities are present in 9.3–44 % (five studies). Lenticular opacities and RPE degeneration correlated positively with use of desferrioxamine and deferriprone respectively (two studies). Ocular fundus abnormalities characteristic of pseudoxanthoma elasticum (PXE), including peau d’orange, angioid streaks, pattern dystrophy-like changes, and optic disc drusen are a consistent finding in seven studies. Patients with PXE-like fundus changes were older than patients without these fundus changes (two studies). Age (two studies) and splenectomy (one study) had the strongest association with presence of PXE-like fundus changes. Increased retinal vascular tortuosity independently of the PXE-like fundus changes was found in 11–17.9 % (three studies), which was associated with aspartate amino transferase, hemoglobin and ferritin levels (two studies). Fundus autofluorescence and electrophysiological testing (ERG and EOG) may indicate initial stages or more widespread injury than is suggested by fundus examination (two studies). CONCLUSIONS: Beta-thalassemia may present with various signs, both structural and functional. Pseudoxanthoma elasticum like fundus changes are a frequent finding in patients with b-thalassemia. These changes increase with duration or severity of the disease. Retinal vascular tortuosity may be an additional disease manifestation related to the severity and duration of anemia and independent of the PXE-like syndrome. Patients with long-standing disease need regular ophthalmic checkups because they are at risk of developing PXE-like fundus changes and potentially of subsequent choroidal neovascularization.
format Online
Article
Text
id pubmed-4938965
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49389652016-07-10 β-Thalassemia and ocular implications: a systematic review Liaska, Aliki Petrou, Petros Georgakopoulos, Constantinos D. Diamanti, Ramza Papaconstantinou, Dimitris Kanakis, Menelaos G. Georgalas, Ilias BMC Ophthalmol Research Article BACKGROUND: Beta-thalassemia is a severe genetic blood disorder caused by a mutation in the gene encoding for the beta chains of hemoglobin. Individuals with beta-thalassemia major require regular lifelong Red Blood Cell transfusions to survive. Ocular involvement is quite common and may have serious implications. METHODS: Extensive review of observational studies on beta-thalassemia, to determine the prevalence and spectrum of ocular abnormalities, by clinical examination and multimodal imaging, and to investigate risk factors for their development. RESULTS: Frequency of ocular involvement differs among various studies (41.3–85 %, three studies). Ocular findings in beta-thalassemia may correlate to the disease itself, iron overload or the chelating agents used. Beta-thalassemia ocular manifestations include ocular surface disease, as demonstrated by tear function parameters (two studies). Lens opacities are present in 9.3–44 % (five studies). Lenticular opacities and RPE degeneration correlated positively with use of desferrioxamine and deferriprone respectively (two studies). Ocular fundus abnormalities characteristic of pseudoxanthoma elasticum (PXE), including peau d’orange, angioid streaks, pattern dystrophy-like changes, and optic disc drusen are a consistent finding in seven studies. Patients with PXE-like fundus changes were older than patients without these fundus changes (two studies). Age (two studies) and splenectomy (one study) had the strongest association with presence of PXE-like fundus changes. Increased retinal vascular tortuosity independently of the PXE-like fundus changes was found in 11–17.9 % (three studies), which was associated with aspartate amino transferase, hemoglobin and ferritin levels (two studies). Fundus autofluorescence and electrophysiological testing (ERG and EOG) may indicate initial stages or more widespread injury than is suggested by fundus examination (two studies). CONCLUSIONS: Beta-thalassemia may present with various signs, both structural and functional. Pseudoxanthoma elasticum like fundus changes are a frequent finding in patients with b-thalassemia. These changes increase with duration or severity of the disease. Retinal vascular tortuosity may be an additional disease manifestation related to the severity and duration of anemia and independent of the PXE-like syndrome. Patients with long-standing disease need regular ophthalmic checkups because they are at risk of developing PXE-like fundus changes and potentially of subsequent choroidal neovascularization. BioMed Central 2016-07-08 /pmc/articles/PMC4938965/ /pubmed/27390837 http://dx.doi.org/10.1186/s12886-016-0285-2 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Liaska, Aliki
Petrou, Petros
Georgakopoulos, Constantinos D.
Diamanti, Ramza
Papaconstantinou, Dimitris
Kanakis, Menelaos G.
Georgalas, Ilias
β-Thalassemia and ocular implications: a systematic review
title β-Thalassemia and ocular implications: a systematic review
title_full β-Thalassemia and ocular implications: a systematic review
title_fullStr β-Thalassemia and ocular implications: a systematic review
title_full_unstemmed β-Thalassemia and ocular implications: a systematic review
title_short β-Thalassemia and ocular implications: a systematic review
title_sort β-thalassemia and ocular implications: a systematic review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938965/
https://www.ncbi.nlm.nih.gov/pubmed/27390837
http://dx.doi.org/10.1186/s12886-016-0285-2
work_keys_str_mv AT liaskaaliki bthalassemiaandocularimplicationsasystematicreview
AT petroupetros bthalassemiaandocularimplicationsasystematicreview
AT georgakopoulosconstantinosd bthalassemiaandocularimplicationsasystematicreview
AT diamantiramza bthalassemiaandocularimplicationsasystematicreview
AT papaconstantinoudimitris bthalassemiaandocularimplicationsasystematicreview
AT kanakismenelaosg bthalassemiaandocularimplicationsasystematicreview
AT georgalasilias bthalassemiaandocularimplicationsasystematicreview